There are two things, and I think Phil touched on this. Peer review is very important for scientific journals, and when you're talking about medicine and therapeutics, peer review, when it comes to economic analysis, is more around research methodology, but they don't really typically question the assumptions built into that. When there's a fundamental difference between the costing study that we did and the Morgan study, it's all around the assumptions—for example, the exchange rate.
Do I think our study has credibility? I do, because unlike Professor Morgan, who has no real-world experience, our researcher actually worked in the federal government and worked with PMPRB. He's actually lived in the real world.